Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy.
about
Management of HCV infection and liver transplantation.Challenges of recurrent hepatitis C in the liver transplant patientG-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrenceLiving donor liver transplantation to patients with hepatitis C virus cirrhosis.Antiviral treatment for hepatitis C virus infection after liver transplantation.Prevention of hepatitis C recurrence after liver transplantation: An update.Management of hepatitis C in liver transplant recipients.Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis.Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients.Treating viral hepatitis C: efficacy, side effects, and complications.Living-donor liver transplantation and hepatitis CRecurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop.Present and future therapy for hepatitis C virus.Rejection under alpha interferon therapy in liver transplant recipients.Therapeutic management of recurrent hepatitis C after liver transplantation.PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus.Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation.Post-transplant liver biopsy and the immune response: lessons for the clinician.Hepatitis C virus and liver transplantation: where do we stand?Developing therapies to treat hepatitis C infection in post-liver transplant recipients.Antihepatitis C virus therapy in liver transplanted patients.Slower Fibrosis Progression Among Liver Transplant Recipients With Sustained Virological Response After Hepatitis C Treatment.Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.Viral hepatitis in solid organ transplantation.Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation.Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin.Viral hepatitis after liver transplantation.Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office.Fibrosing cholestatic hepatitis with hepatitis C virus treated by double filtration plasmapheresis and interferon plus ribavirin after liver transplantation.Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation.Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C.Impact of pegylated interferon alpha-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.Liver transplantation and hepatitis C
P2860
Q24541563-540B9EF8-F7EE-481F-884C-647640218438Q27011871-60CDE589-6FCF-4A08-8645-513E69F6FF51Q27490405-534980D5-D9A4-4FA5-8C1E-5FAD8FE4E717Q34017608-4305D586-6F5C-45BA-9D46-09AA2BD0F842Q34340293-5ABE7299-6F82-4356-BE88-C287C4C16196Q36220172-13AFF07C-3A6B-48B7-8EB5-D8988CA5371AQ36392142-E4F7A02A-7731-49B8-BBAC-E70F0B8E3A4FQ36530402-B240CDE3-F7A8-4732-8C2A-9FF8F0F7CF62Q36547798-B0A8434C-01FA-4CA3-B6BD-D30B3DE002E9Q36564615-FD5A7071-5828-4A76-B0B9-344968F1B9A7Q36587253-88893487-7B79-402B-B903-C1E346565C54Q36655931-B4B961B0-DDC4-4064-B9B6-DD2E78582AECQ36670887-724605F5-656A-4E64-99DA-E175C6664141Q36709673-05BCB24E-3677-4E30-89FF-C183A41374ABQ36758660-00EF84A7-1DF3-4E1F-9C0F-96436C78DBCBQ37077437-3F86107E-E8AC-40C3-B891-EF030A5E5A22Q37973516-600ED394-F0DE-4169-B6EB-CE3CF24FC404Q38053173-CAF81875-2DAC-4657-81B8-A4089D07865CQ38551818-A2E01EAB-CC1A-4531-AB1F-8ED797BCF59AQ39055696-468A1E54-F512-4DB1-BF01-EFFF46DEBD9CQ39887907-5C643FB6-56F1-4C4A-B4EA-4068B59A0EAFQ40482753-A3D37743-F651-4484-B591-D2D335BC45D2Q40576603-D018BE21-A973-401F-8BD2-0A277D909F84Q42272319-4BADA93D-15D6-4093-BC8F-A1DFA01FD63FQ42998971-8186CF14-5BD3-4D35-AF3A-72AE3A90FE19Q43001526-781F93E1-1068-4E9B-9EA7-D10AEA41F26AQ43453679-F12D5EF7-9C19-4C9E-8348-3E006AFDE460Q44097379-E47666B7-4589-4612-844A-5B4758977803Q45341299-E46A4687-BA55-496F-8E86-4DA8027178F2Q46738356-2BAEAE35-44A1-4C96-AF23-2CC13B66E943Q50575004-9996E182-966F-4FC7-9D96-C503237BB029Q50576126-35CE0BCF-C969-4C91-827C-0C16A22292A7Q58704499-75DFB8C2-5917-4295-B149-40A62EB698A8
P2860
Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Treatment of established recur ...... alfa-2b and ribavirin therapy.
@ast
Treatment of established recur ...... alfa-2b and ribavirin therapy.
@en
type
label
Treatment of established recur ...... alfa-2b and ribavirin therapy.
@ast
Treatment of established recur ...... alfa-2b and ribavirin therapy.
@en
prefLabel
Treatment of established recur ...... alfa-2b and ribavirin therapy.
@ast
Treatment of established recur ...... alfa-2b and ribavirin therapy.
@en
P2093
P1433
P1476
Treatment of established recur ...... alfa-2b and ribavirin therapy.
@en
P2093
Amr S Khaled
Christopher B O'Brien
Eugene R Schiff
Gabriella Slapak-Green
Guy W Neff
Kamran Safdar
Maria De Medina
Marzia Montalbano
P304
P356
10.1097/01.TP.0000129811.93072.1C
P577
2004-11-01T00:00:00Z